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Introduction 
Lung cancer is one of the most common malignancies
in the world. Despite major advances in the lung can-
cer treatment over the past two decades, the progno-
sis of patients with lung cancer has improved only
minimally. The poor outcome of the disease may be
attributed to its late diagnosis, low cure rate for
advanced stage tumors, and the poor understanding
of biology of the lung tumors. Additionally, there is a
need for improved clinical stratification methods that
can identify lung cancer patients with high risk of
recurrence and poor prognosis after curative surgical
resection.
Until today the TNM staging system has remained
the most powerful tool for medical decision making in
NSCLC  patients. 
Whereas the 5-year survival rate for patients with
stage I disease is about 70%, it decreases to 30% in
stage IIIa [1]. 
On the other hand, however, TNM staging system
makes it difficult to accurately predict the prognosis for
each patient. For example, even patients with stage I dis-
ease, have only a 65-80% survival rate at 5 years, after
they undergo a curative surgery. It is therefore important
to evaluate more accurate tools, independent from TNM
staging system to predict prognosis in these patients.
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Abstract. The epigenetic inactivation of tumor suppressor genes may play an important role in the development and pro-
gression of many cancer types, including lung cancer. Therefore, we investigated the association between the aberrant pro-
moter methylation of 2 genes: the Death-Associated Protein Kinase (DAPK) and the Ras Association Domain Family 1A
(RASSF1A) by using methylation-specific PCR, and the clinicopathological features and prognosis in 70 radically resected
non-small cell lung cancers (NSCLCs). Hypermethylation of the DAPK and RASSF1A promoters was found in 24 (34%),
and in 18 (26%) tumor DNA samples, respectively. Regarding different clinicopathological features of NSCLCs, the DAPK
promoter methylation was more frequently observed in squamous cell carcinoma (46%) than in adenocarcinoma (25%) and
large cell carcinoma (22%), but there were no significant statistical differences (p=0.3). On the other hand, a statistically
significant trend was observed between the RASSF1A methylation  and a histological type of tumor (p=0.06). 45% of ade-
nocarcinoma tumors showed RASSF1A promoter methylation in comparison to 17% of squamous cell carcinomas and 22%
of large cell carcinomas. When both markers were analyzed according to the tumor-node-metastasis (TNM) staging system,
no statistically significant differences were observed between stage I, II and IIIa, and the DAPK (p=0.2) and RASSF1A
methylation (p=0.1). In comparison, when stage I and II were grouped together and considered vs. stage IIIa, a significant
association between RASSF1A methylation and the TNM was found (p=0.03). The group of patients with tumors showing
DAPK promoter methylation had significantly poorer overall survival rates (p=0.02) than the patients with tumors that did
not show DAPK promoter methylation. However, the association between the RASSF1A promoter methylation status and
the overall survival rates was not statistically significant (p=0.48). In conclusion, this paper supports the importance of epi-
genetic gene regulation in lung cancer progression and prognosis. 
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In recent years, it has become apparent that lung
cancer represents not only the result of multiple muta-
tions, but also the loss of gene function by aberrant
methylation of CpG islands in promoter regions. Since
the aberrant methylation of normally unmethylated
CpG-rich areas of the promoter region has been shown
to lead to the silencing of mRNA expression, this epi-
genetic alteration is considered to be a significant
mechanism for inactivation of these tumor suppressor
genes in lung cancer [2].
Aberrant promoter methylation has been described
for several genes in lung cancer, including  the newly
identified tumor suppressor genes DAPK and
RASSF1A.
The DAPK gene is located on chromosome 9q34. 1.
It encodes a proapoptotic protein involved in the apop-
tosis initiated by THN-α, IFN-γ, Fas and TRAIL.
Aggressiveness of malignant tumors has been associ-
ated with the methylation of the promoter region of the
DAPK gene and the loss of DAPK expression [3]. Anal-
ysis for DAPK mRNA and protein in neoplastic B-cell
lines, bladder carcinoma cells, and renal cell carcinoma
cells found a lack of expression. The expression was
partially restored by treatment with 5'-aza-2'-deoxyciti-
dine (a demethylation agent) indicating a role for
methylation in down regulation of DAPK [4].
The RASSF1A gene is located within a 120-kb
region of chromosome 3p21, a region that is epigenet-
ically inactivated at high frequency in NSCLC.
RASSF1A has been shown to bind to the Ras-GTP
binding protein Nore1, consistent with its role as a
negative effector of Ras oncoprotein [5]. 
It has also been suggested that RASSF1A is an
important tumor suppressor gene acting at the level of
G1/S phase cell cycle progression [6]. 
It has been shown that the RASSF1A promoter is
hypermethylated in lung cancer cells and that the
exogenous expression of RASSF1A expresses tumori-
genesis in nude mice [7]. Additionally,  it has been
reported that the RASSF1A gene is frequently inacti-
vated in primary lung cancers by the de novo methyla-
tion of CpG islands in the promoter region [8,9].
In the present study, we investigated the association
between the aberrant promoter methylation of the
DAPK and RASSF1A genes, and the clinicopathologi-
cal features and prognosis in radically resected
NSCLCs. 
Material and methods
Patients. The study includes 70 NSCLC patients (33 stage I, 22
stage II and 15 stage IIIa) examined by the Chest Oncology
Group and operated in the Thoracic Surgery Unit at the Bia-
lystok Medical University. All of these patients underwent sur-
gical resection.
Pretreatment staging procedures included physical and blood
examinations, chest radiographs and tomographs, bronchoscopy,
computed tomography (CT) of the thorax and ultrasound scanning
of liver. In addition, radioisotopic scans of bones, examination of
bone marrow aspirates, and abdominal and brain CT scan were
performed when necessary. Selected patients underwent medi-
astinoscopy.  Pathological material has been specially reviewed for
this study by the same pathologist. Postoperative, pathological
staging (pTNM) was performed by correlating the operative and
histological findings.
Methods. Tumor DNA was isolated and purified according to con-
ventional methods. DNA from serum was extracted using a QIAmp
Blood Mini Kit (Qiagen, Germany) following the protocol for
blood and body fluids, modified as described elsewhere. Purified
DNA was chemically modified by sodium bisulfite. The methyla-
tion-specific PCR (MS-PCR) was performed according to the
method of Herman et al. [10].The two sets of primers were used,
one specific for DNA methylated at the promoter region of each
gene and the other specific for unmethylated DNA. The DNA
sequence of primes, conditions of the reaction, and sizes of PCR
products in MS-PCR are described in Table 1. 
Statistical analysis. The association between the promoter methy-
lation status of  DAPK and RASSF1A and the clinicopathological
characteristics was analysed using chi-squared test. The effect of
methylation on patient survival was estimated by the Kaplan-Meier
method and the differences between two groups were compared
using the log-rank test. 
The Cox univariate proportional hazards regression model was
used to estimate the HR of factors influencing patient's survival.
The analysis was performed using Statistic 8.0 program.
Results
Methylation status of the CpG islands at the promoter
regions of DAPK and RASSF1A genes was analysed by
MS-PCR in frozen NSCLC tissue (Fig. 1). Hyperme-
thylation of the DAPK and RASSF1A promoters was
found in 24 (34%),  and  in 18 (26%) of the tumor
DNA samples, respectively. 
Regarding different clinicopathological features of
NSCLCs, DAPK promoter methylation was more fre-
quently observed in squamous cell carcinoma (46%)
than in adenocarcinoma (25%) and large cell carcinoma
(22%), but there was no statistically significant differ-
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Table 1. The sequence of primes, conditions of the reaction, and sizes of PCR products in MS-PCR
ences (p=0.3). On the other hand, a statistically signifi-
cant trend was observed between RASSF1A methylation
and histological type of tumor (p=0.06). 45% of adeno-
carcinoma tumors showed RASSF1A promoter methyla-
tion in comparison to 17% of squamous cell carcinomas
and 22% of large cell carcinomas (Table 2).
When the both markers were analyzed according to
the TNM stage of disease, there was no statistically
significant differences between I, II and IIIa stages and
DAPK methylation (p=0.2) and RASSF1A methylation
(p=0.1). On the other hand, there was a significant
association between RASSF1A methylation and TNM
when stages I and II were considered together vs. stage
IIIa (p=0.03).
We then analyzed the effect of DAPK and RASSF1A
promoter methylation on the patient survival.
The group of patients with tumors containing
DAPK promoter methylation had significantly poorer
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Fig. 1. Methylation analysis of
DAPK (A) and RASSF1A (B) pro-
moters in NSCLC. MSP for DAPK
and RASSF1A was performed
using unmethylation-specific (U)
and methylation-specific (M)
primer sets. Molecular weight
markers are listed on left side. 
Table 2. Proportions of positive results of the DAPK and RASSF1A promoter hypermethylation by histological type and TNM stage of
non-small cell lung cancer
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overall survival rates (p=0.02) then the patients with
tumors that did not contain DAPK promoter methyla-
tion (Fig. 2A). However, the association between the
RASSF1A promoter methylation status and overall sur-
vival rates was not statistically significant
(p=0.48)(Fig. 2B). The results were confirmed using
univariate proportional hazards regression model 
(p=0.05, HR 1.903 for DAPK and p=0.81, HR 1.088
for RASSF1A) (Table 3).
Fig. 2. Kaplan-Meier survival curves
for overall survival in non-small cell
lung cancer patients and DAPK (A)
and RASSF1A (B) promoter methyla-
tion status.
Table 3. The Cox univariate proportional hazard regression model
of survival
Discussion
In lung cancer, several biological and molecular fac-
tors have been used to evaluate tumor progression as a
prognostic indicator. We have previously reported the
prognostic significance of some molecular factors,
such as p53 and VEGF alterations [11].
Promoter DNA methylation plays an important role
in tumor development by regulating the expression of
specific genes [12].
In lung cancer, methylation has been observed in
many tumor suppressor genes, including DAPK and
RASSF1A.
In this study, we investigated the relationship
between the promoter methylation of DAPK and
RASSF1A tumor suppressor genes, and clinicopatholog-
ical parameters and prognosis of patients with
respectable NSCLC. We have found that the DAPK pro-
moter methylation was more frequently observed in
squamous cell carcinoma than in adenocarcinoma and
large cell carcinoma, but there were no statistically sig-
nificant differences. On the other hand, a statistically
significant trend was observed between the RASSF1A
methylation and lung adenocarcinoma. Some previous
reports are consistent with these findings [13].
Regarding the TNM stage of disease we found no
statistically significant differences between stage I, II
and IIIa and the DAPK and RASSF1A promoter methy-
lation. Similar results were obtained by Kim et al.
[14,15] who did not show any correlation between the
DAPK and RASSF1A methylation status and the TNM
stage. 
In this paper, we have also studied the prognostic
significance of DAPK and RASSF1A in surgically
treated NSCLC. 
We found that the patients with tumors showing
the DAPK promoter methylation had significantly
poorer overall survival rates than the patients with
tumors that did not show the DAPK promoter methy-
lation. 
Other reports have also demonstrated an interesting
association between the methylation status of DAPK
tumor suppressor gene and the prognosis.
Lu et al. [16] have analyzed the panel of six bio-
markers in the population of resected stage I NSCLC
patients, and have demonstrated that the DAPK pro-
moter methylation was the most statistically signifi-
cant predictor of survival for these patients. Similar
results were shown by Tang et al. [17]. They have also
found the significant association of the DAPK methy-
lation with poorer overall and disease-free survival in
stage I NSCLC patients.
Kim et al. [18] investigated the role of the DAPK
methylation in 185 NSCLC patients who underwent
surgical resection, including 102 patients with stage I
disease. The DAPK methylation was significantly cor-
related with advanced stage, including lymph node
involvement. Stage I patients with the DAPK methyla-
tion had worse overall survival, although this associa-
tion was not statistically significant. 
In our study we have also investigated the prognos-
tic significance of the RASSF1A methylation in
NSCLC. We have found that the association between
the RASSF1A promoter methylation status and the
overall survival rates was not statistically significant.
Similar results were obtained in two other studies
showing no significant correlation between RASSF1A
methylation and prognosis of NSCLC patients [19,20].
In the study by Wang et al. [21] patients whose stage
I/II tumors carried RASSF1A promoter methylation had
poorer 5-year survival rate, but the association was not
statistically significant. In patients with stage IIIa dis-
ease, however, RASSF1A promoter hypermethylation
was a stronger independent predictor of survival. 
On the other hand, the methylation status of RASSF1A
has been reported to be significantly associated with a
poor survival in some other papers [22-24]. Yanagawa et
al. [24] additionally showed that patients with RASSF1A
methylation positive had a shorter survival in squamous
cell carcinoma than in adenocarcinoma. 
Published reports and our results showed in this
paper support the importance of epigenetic gene reg-
ulation in lung cancer progression and prognosis.
However, additional studies are necessary to prove
the prognostic significance of promoter methylation
of DAPK and RASSF1A in patients with NSCLC.
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